Table 2 Treatment responses

From: Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study

 

Intention-to-treat population (n = 40)

Per-protocol population (n = 38)a

Complete response

0

0

Partial response

7 (17.5%)

7 (18.4%)

Stable disease

23 (57.5%)

23 (60.5%)

Disease progression

8 (20.0%)

8 (21.1%)

Overall response

7 (17.5%; 5.2–29.8)

7 (18.4%; 5.5–31.3)

Disease control

30 (75.0%; 61–89)

30 (78.9%; 65.4–92.5)

  1. The data presented as n (%)
  2. aTwo patients were excluded because there was no post-baseline efficacy assessment
Back to article page